Kronos Financial Statements From 2010 to 2025

KRON Stock  USD 0.93  0.02  2.11%   
Kronos Bio financial statements provide useful quarterly and yearly information to potential Kronos Bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kronos Bio financial statements helps investors assess Kronos Bio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Kronos Bio's valuation are summarized below:
Gross Profit
9.9 M
Market Capitalization
57.3 M
Revenue
9.9 M
Earnings Share
(1.43)
Quarterly Revenue Growth
1.585
We have found one hundred twenty available fundamental ratios for Kronos Bio, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Kronos Bio's last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to drop to about 99.5 M. In addition to that, Enterprise Value is likely to drop to about 50.4 M

Kronos Bio Total Revenue

7.59 Million

Check Kronos Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kronos Bio's main balance sheet or income statement drivers, such as Net Interest Income of 10.9 M, Interest Income of 10.9 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 9.18, Dividend Yield of 0.0 or PTB Ratio of 0.43. Kronos financial statements analysis is a perfect complement when working with Kronos Bio Valuation or Volatility modules.
  
Check out the analysis of Kronos Bio Correlation against competitors.
To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.

Kronos Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets279.9 M245.3 M134.6 M
Slightly volatile
Short and Long Term Debt Total23.2 M32.5 M11.8 M
Slightly volatile
Other Current Liabilities13.5 M12.9 M3.7 M
Slightly volatile
Total Current Liabilities29.8 M28.4 M9.1 M
Slightly volatile
Other Liabilities228.3 K240.3 K330 K
Slightly volatile
Property Plant And Equipment Net28.7 M34.4 M14.6 M
Slightly volatile
Current Deferred Revenue6.1 M11 M3.2 M
Slightly volatile
Accounts Payable964.7 KM1.4 M
Slightly volatile
Cash70.3 M74 M75.7 M
Slightly volatile
Non Current Assets Total42.7 M39.7 M20.7 M
Slightly volatile
Non Currrent Assets Other1.6 MM974.5 K
Slightly volatile
Other Assets3.5 M3.7 M6.1 M
Pretty Stable
Cash And Short Term Investments242.9 M198.9 M115.5 M
Slightly volatile
Common Stock Total Equity39.2 K65.5 K23.7 K
Slightly volatile
Common Stock Shares Outstanding55.8 M66.4 M40.9 M
Slightly volatile
Liabilities And Stockholders Equity279.9 M245.3 M134.6 M
Slightly volatile
Non Current Liabilities Total35.5 M26.6 M29.8 M
Slightly volatile
Capital Lease Obligations23.2 M32.5 M11.8 M
Slightly volatile
Other Current Assets4.9 M6.6 M2.5 M
Slightly volatile
Total Liabilities45.8 M48.8 M37.3 M
Slightly volatile
Property Plant And Equipment Gross44.9 M42.8 M13.6 M
Slightly volatile
Total Current Assets237.3 M205.6 M113.8 M
Slightly volatile
Capital Stock43.5 K67.8 K24.3 K
Slightly volatile
Non Current Liabilities Other228.3 K240.3 K351.2 K
Pretty Stable
Net Working Capital223.2 M177.2 M105.7 M
Slightly volatile
Short Term Debt7.1 M6.8 M1.9 M
Slightly volatile
Common Stock43.5 K67.8 K24.3 K
Slightly volatile
Property Plant Equipment22.4 M14.9 M10.4 M
Slightly volatile
Net Receivables604.5 K657.8 K363.4 K
Slightly volatile
Capital Surpluse669.9 M737.6 M603.1 M
Slightly volatile

Kronos Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M2.5 M935 K
Slightly volatile
Interest Expense11.1 M10.5 M2.5 M
Slightly volatile
Selling General Administrative26.3 M48 M14.4 M
Slightly volatile
Other Operating Expenses91.3 M147.3 M49.4 M
Slightly volatile
Research Development65 M99.3 M35 M
Slightly volatile
Total Operating Expenses91.3 M147.3 M49.4 M
Slightly volatile
Reconciled Depreciation1.4 M2.6 M779.9 K
Slightly volatile
Cost Of Revenue4.2 M5.7 M2.1 M
Slightly volatile
Selling And Marketing ExpensesM3.4 M3.7 M
Slightly volatile

Kronos Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.8 M28.7 M8.2 M
Slightly volatile
Begin Period Cash Flow105 M89.7 M48.7 M
Slightly volatile
Other Cashflows From Financing Activities484.8 K510.3 K32.7 M
Very volatile
Depreciation1.4 M2.5 M765.9 K
Slightly volatile
Other Non Cash Items937.9 K987.3 KM
Pretty Stable
Capital Expenditures580.5 K611.1 K1.8 M
Pretty Stable
Total Cash From Financing Activities484.8 K510.3 K42.1 M
Very volatile
End Period Cash Flow116.9 M76.3 M57 M
Slightly volatile
Change To Netincome21.7 M37 M11.9 M
Slightly volatile
Sale Purchase Of Stock460 K484.2 K182 M
Slightly volatile
Dividends Paid3.6 MM4.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.1810.3311.2635
Slightly volatile
Stock Based Compensation To Revenue3.183.583.8988
Slightly volatile
Capex To Depreciation0.350.378.0907
Slightly volatile
EV To Sales4.65.175.6377
Slightly volatile
Payables Turnover1.060.80.6901
Slightly volatile
Sales General And Administrative To Revenue5.315.976.5131
Slightly volatile
Research And Ddevelopement To Revenue10.9912.3613.4794
Slightly volatile
Capex To Revenue0.0880.09720.1061
Slightly volatile
Cash Per Share3.962.72.4528
Slightly volatile
Days Payables Outstanding7754751.2 K
Slightly volatile
Income Quality0.830.80.8613
Slightly volatile
Net Debt To EBITDA0.330.351.4996
Pretty Stable
Current Ratio7.918.3312.4981
Pretty Stable
Capex Per Share0.01280.01350.0437
Very volatile
Revenue Per Share0.0880.0980.1069
Slightly volatile
Interest Debt Per Share0.310.440.2095
Slightly volatile
Debt To Assets0.06040.120.0702
Slightly volatile
Days Of Payables Outstanding7754751.2 K
Slightly volatile
Ebt Per Ebit1.171.061.0443
Pretty Stable
Effective Tax Rate0.02510.02640.0335
Pretty Stable
Quick Ratio7.918.3312.7777
Pretty Stable
Net Income Per E B T0.730.870.9262
Slightly volatile
Cash Ratio2.853.09.6954
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.221.161.1488
Slightly volatile
Fixed Asset Turnover0.170.190.2065
Slightly volatile
Debt Ratio0.06040.120.0702
Slightly volatile
Price Sales Ratio9.1810.3311.2635
Slightly volatile
Asset Turnover0.02360.02650.0289
Slightly volatile

Kronos Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap99.5 M104.7 M694.6 M
Slightly volatile
Enterprise Value50.4 M53.1 M629.4 M
Slightly volatile

Kronos Fundamental Market Drivers

Cash And Short Term Investments173 M

Kronos Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Kronos Bio Financial Statements

Kronos Bio investors utilize fundamental indicators, such as revenue or net income, to predict how Kronos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11 M6.1 M
Total Revenue7.2 M7.6 M
Cost Of Revenue5.7 M4.2 M
Stock Based Compensation To Revenue 3.58  3.18 
Sales General And Administrative To Revenue 5.97  5.31 
Research And Ddevelopement To Revenue 12.36  10.99 
Capex To Revenue 0.10  0.09 
Revenue Per Share 0.10  0.09 
Ebit Per Revenue(17.44)(18.31)

Pair Trading with Kronos Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kronos Stock

  0.67A Agilent TechnologiesPairCorr

Moving against Kronos Stock

  0.38DVAX Dynavax TechnologiesPairCorr
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Kronos Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kronos Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kronos Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kronos Bio Stock:
Check out the analysis of Kronos Bio Correlation against competitors.
To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.166
Quarterly Revenue Growth
1.585
Return On Assets
(0.25)
Return On Equity
(0.59)
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.